TSBX vs. FGEN, ALLK, INKT, CALC, SCLX, RANI, GRCE, CVKD, ABVC, and DARE
Should you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include FibroGen (FGEN), Allakos (ALLK), MiNK Therapeutics (INKT), CalciMedica (CALC), Scilex (SCLX), Rani Therapeutics (RANI), Grace Therapeutics (GRCE), Cadrenal Therapeutics (CVKD), ABVC BioPharma (ABVC), and Daré Bioscience (DARE). These companies are all part of the "pharmaceutical products" industry.
Turnstone Biologics vs.
Turnstone Biologics (NASDAQ:TSBX) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking.
FibroGen received 343 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 58.81% of users gave FibroGen an outperform vote while only 44.44% of users gave Turnstone Biologics an outperform vote.
52.5% of Turnstone Biologics shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 32.1% of Turnstone Biologics shares are owned by company insiders. Comparatively, 3.1% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Turnstone Biologics has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Turnstone Biologics' return on equity.
Turnstone Biologics has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks.
In the previous week, FibroGen had 6 more articles in the media than Turnstone Biologics. MarketBeat recorded 6 mentions for FibroGen and 0 mentions for Turnstone Biologics. Turnstone Biologics' average media sentiment score of 0.00 beat FibroGen's score of -0.90 indicating that Turnstone Biologics is being referred to more favorably in the media.
Turnstone Biologics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
Turnstone Biologics currently has a consensus price target of $0.45, suggesting a potential upside of 32.59%. FibroGen has a consensus price target of $10.00, suggesting a potential upside of 2,944.14%. Given FibroGen's stronger consensus rating and higher possible upside, analysts plainly believe FibroGen is more favorable than Turnstone Biologics.
Summary
FibroGen beats Turnstone Biologics on 11 of the 18 factors compared between the two stocks.
Get Turnstone Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Turnstone Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:TSBX) was last updated on 5/23/2025 by MarketBeat.com Staff
